Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Recent & Breaking News (NDAQ:HALO)

Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference

PR Newswire November 18, 2020

Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For HER2-Positive Breast Cancer

PR Newswire November 13, 2020

Halozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO(TM)/ DARZALEX® Subcutaneous (SC) Formulation Utilizing ENHANZE® Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma

PR Newswire November 12, 2020

MGIC Investment & Halozyme Therapeutics Set to Join S&P MidCap 400; First Bancorp, The Geo Group & Mednax to Join S&P SmallCap 600

PR Newswire November 5, 2020

Halozyme Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZE®

PR Newswire November 5, 2020

Halozyme Reports Third Quarter 2020 Results And Raises Full Year 2020 Guidance

PR Newswire November 2, 2020

Halozyme To Host THIRD Quarter 2020 Financial Results webcast and Conference Call

PR Newswire October 22, 2020

Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE® Technology

PR Newswire October 6, 2020

Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze® In Non-Small Cell Lung Cancer

PR Newswire September 17, 2020

Halozyme Announces Janssen Submission For FDA Approval Of DARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj) For The Treatment Of Patients With Light Chain (AL) Amyloidosis

PR Newswire September 10, 2020

Halozyme To Present At Upcoming Virtual Investor Conferences

PR Newswire September 9, 2020

Halozyme To Participate In 2020 Wells Fargo Virtual Healthcare Conference

PR Newswire September 2, 2020

Halozyme Reports Significant Recent Achievements And Second Quarter 2020 Results

PR Newswire August 10, 2020

Halozyme To Present At Canaccord Genuity 40th Annual Growth Conference

PR Newswire August 4, 2020

Halozyme To Host Second Quarter 2020 Financial Results Webcast And Conference Call

PR Newswire July 29, 2020

Halozyme Announces Roche Receives FDA Approval For Phesgo(TM) (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer

PR Newswire June 29, 2020

Halozyme To Receive $10 Million Milestone Payment From Janssen

PR Newswire June 22, 2020

Halozyme To Participate In The BMO 2020 Prescriptions For Success Healthcare Conference

PR Newswire June 17, 2020

Halozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual Congress

PR Newswire June 13, 2020

Halozyme Announces Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX® Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma

PR Newswire June 4, 2020